Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept Extension in DME (Endurance)
NCT02297204Phase 4Completed
- Sponsor
- Northern California Retina Vitreous Associates
- Start
- Nov 2014
- Primary completion
- Dec 2017
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
01
Overview
A Phase 4 trial of aflibercept in diabetic macular edema (DME), sponsored by Northern California Retina Vitreous Associates. Started Nov 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02297204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02297204.